AA
DSGN icon

AlphaCentric Advisors’s Design Therapeutics DSGN Stock Holding History

AlphaCentric Advisors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Buy
21,537
+306
+1% +$3.81K 0.26% 130
2026
Q1 		$226K Buy
21,231
+969
+5% +$9.8K 0.23% 134
2025
Q4 		$190K Buy
+20,262
New +$159K 0.19% 148

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AlphaCentric Advisors's DSGN Position: Q2 2026 in Review

AlphaCentric Advisors increased its Design Therapeutics (DSGN) stake by 1.4% in Q2 2026, buying an estimated $3.81K and bringing the position to 21,537 shares worth $312K. The position accounts for 0.26% of the portfolio, ranked #130.

AlphaCentric Advisors first reported a position in DSGN in Q4 2025 and has held it in 3 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • AlphaCentric Advisors held 21,537 shares of Design Therapeutics worth $312K as of Q2 2026.
  • AlphaCentric Advisors bought 306 Design Therapeutics shares in Q2 2026, an estimated $3.81K.
  • Design Therapeutics made up 0.26% of AlphaCentric Advisors's portfolio in Q2 2026, its #130 holding.
  • AlphaCentric Advisors first reported a position in Design Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.